Fiche société
Shanghai Juncell Therapeutics
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications1liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| GC203 TILThis study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide. | Cancer | Phase 1 | À vérifier | China | À vérifier |
| GC203 TILThis study is to investigate the safety and efficacy of gene-edited tumor infiltrating lymphocyte (GC203 TIL) therapy in patients with pancreatic ductal adenocarcinoma. Gene-edited TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide. | Cancer | Phase 1 | À vérifier | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| GC203 TIL | Cancer | Phase 1 | NCT06828328 | A Study of GC203 TIL in PDCA (RJ) | RECRUITING |
Publications
1| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| GC203 TIL | PiggyBac-engineered membrane-bound IL-7 TILs combined with anti-PD-1 antibody demonstrates efficacy in recurrent ovarian cancer: a first-in-human phase 1 trial. | Clinical cancer research : an official journal of the American Association for Cancer Research |